The store will not work correctly when cookies are disabled.
JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.
4-(3-methoxy-5-(1H-pyrazol-1-yl)phenoxy)-7-(trifluoromethyl)quinoline ID: ALA5286001
Max Phase: Preclinical
Molecular Formula: C20H14F3N3O2
Molecular Weight: 385.35
Associated Items:
Names and Identifiers Canonical SMILES: COc1cc(Oc2ccnc3cc(C(F)(F)F)ccc23)cc(-n2cccn2)c1
Standard InChI: InChI=1S/C20H14F3N3O2/c1-27-15-10-14(26-8-2-6-25-26)11-16(12-15)28-19-5-7-24-18-9-13(20(21,22)23)3-4-17(18)19/h2-12H,1H3
Standard InChI Key: VXIAGSJUSRMDQP-UHFFFAOYSA-N
Molfile:
RDKit 2D
28 31 0 0 0 0 0 0 0 0999 V2000
1.8687 0.6187 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.1541 0.2064 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.4395 0.6187 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.4395 1.4432 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.1541 1.8554 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.8687 1.4432 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
1.1541 2.6800 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
1.8687 3.0922 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.2749 0.2064 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
-0.2749 -0.6180 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.4395 -1.0302 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
0.4395 -1.8547 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.2749 -2.2670 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-0.9895 -1.8547 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-0.9895 -1.0302 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.7041 -0.6180 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.4186 -1.0302 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-2.4186 -1.8547 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-1.7041 -2.2670 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
2.5833 0.2064 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
2.5833 -0.6180 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.3803 -0.8653 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.8475 -0.2057 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.3528 0.4538 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
-3.1331 -2.2672 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
-3.1331 -3.0922 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
-3.8475 -1.8547 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
-3.8475 -2.6797 0.0000 F 0 0 0 0 0 0 0 0 0 0 0 0
1 2 1 0
2 3 2 0
3 4 1 0
4 5 2 0
5 6 1 0
6 1 2 0
5 7 1 0
7 8 1 0
9 3 1 0
10 9 1 0
11 10 2 0
12 11 1 0
13 12 2 0
14 13 1 0
14 15 2 0
15 10 1 0
15 16 1 0
16 17 2 0
17 18 1 0
18 19 2 0
19 14 1 0
20 1 1 0
20 21 1 0
21 22 2 0
22 23 1 0
24 23 2 0
20 24 1 0
18 25 1 0
25 26 1 0
25 27 1 0
25 28 1 0
M END Associated Targets(Human) Molecule Features Natural Product: NoOral: NoChemical Probe: NoParenteral: NoMolecule Type: Topical: NoFirst In Class: NoBlack Box: NoChirality: NoAvailability: NoProdrug: No
Drug Indications MESH ID MESH Heading EFO IDs EFO Terms Max Phase for Indication References
Mechanisms of Action Mechanism of Action Action Type target ID Target Name Target Type Target Organism Binding Site Name References
Calculated Properties Molecular Weight: 385.35Molecular Weight (Monoisotopic): 385.1038AlogP: 5.24#Rotatable Bonds: 4Polar Surface Area: 49.17Molecular Species: NEUTRALHBA: 5HBD: ┄#RO5 Violations: 1HBA (Lipinski): 5HBD (Lipinski): ┄#RO5 Violations (Lipinski): 1CX Acidic pKa: ┄CX Basic pKa: 4.68CX LogP: 4.44CX LogD: 4.44Aromatic Rings: 4Heavy Atoms: 28QED Weighted: 0.48Np Likeness Score: -1.55
References 1. Lv G, Shi Q, Zhang T, Li J, Long Y, Zhang W, Choudhry N, Yang K, Li H, Kalashova J, Yang C, Zhou X, Reddy MC, Anantoju KK, Zhang S, Zhang J, Allen TD, Liu H, Nimishetti N, Yang D.. (2023) Integrating a phenotypic screening with a structural simplification strategy to identify 4-phenoxy-quinoline derivatives to potently disrupt the mitotic localization of Aurora kinase B., 80 [PMID:36696874 ] [10.1016/j.bmc.2023.117173 ]